Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 0.92
TKPYY's Cash to Debt is ranked lower than
57% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.63 vs. TKPYY: 0.92 )
Ranked among companies with meaningful Cash to Debt only.
TKPYY' s Cash to Debt Range Over the Past 10 Years
Min: 0.7  Med: 50.01 Max: N/A
Current: 0.92
Equity to Asset 0.50
TKPYY's Equity to Asset is ranked lower than
69% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. TKPYY: 0.50 )
Ranked among companies with meaningful Equity to Asset only.
TKPYY' s Equity to Asset Range Over the Past 10 Years
Min: 0.5  Med: 0.56 Max: 0.76
Current: 0.5
0.5
0.76
F-Score: 5
Z-Score: 2.31
M-Score: -3.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) -7.40
TKPYY's Operating margin (%) is ranked lower than
79% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.82 vs. TKPYY: -7.40 )
Ranked among companies with meaningful Operating margin (%) only.
TKPYY' s Operating margin (%) Range Over the Past 10 Years
Min: -7.27  Med: 22.89 Max: 35.13
Current: -7.4
-7.27
35.13
Net-margin (%) -8.25
TKPYY's Net-margin (%) is ranked lower than
80% of the 687 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.45 vs. TKPYY: -8.25 )
Ranked among companies with meaningful Net-margin (%) only.
TKPYY' s Net-margin (%) Range Over the Past 10 Years
Min: -8.05  Med: 16.44 Max: 25.85
Current: -8.25
-8.05
25.85
ROE (%) -6.71
TKPYY's ROE (%) is ranked lower than
76% of the 715 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.30 vs. TKPYY: -6.71 )
Ranked among companies with meaningful ROE (%) only.
TKPYY' s ROE (%) Range Over the Past 10 Years
Min: -6.33  Med: 11.31 Max: 15.02
Current: -6.71
-6.33
15.02
ROA (%) -3.42
TKPYY's ROA (%) is ranked lower than
74% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.67 vs. TKPYY: -3.42 )
Ranked among companies with meaningful ROA (%) only.
TKPYY' s ROA (%) Range Over the Past 10 Years
Min: -3.23  Med: 8.64 Max: 12
Current: -3.42
-3.23
12
ROC (Joel Greenblatt) (%) -19.25
TKPYY's ROC (Joel Greenblatt) (%) is ranked lower than
78% of the 735 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.76 vs. TKPYY: -19.25 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TKPYY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -19.36  Med: 67.70 Max: 210.61
Current: -19.25
-19.36
210.61
Revenue Growth (3Y)(%) 5.80
TKPYY's Revenue Growth (3Y)(%) is ranked higher than
50% of the 585 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. TKPYY: 5.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TKPYY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0.2  Med: 4.90 Max: 11.6
Current: 5.8
0.2
11.6
EBITDA Growth (3Y)(%) -28.30
TKPYY's EBITDA Growth (3Y)(%) is ranked lower than
87% of the 531 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. TKPYY: -28.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TKPYY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -28.3  Med: 1.30 Max: 24.8
Current: -28.3
-28.3
24.8
» TKPYY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with TKPYY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 22.12
TKPYY's Forward P/E is ranked lower than
66% of the 408 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.75 vs. TKPYY: 22.12 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 2.13
TKPYY's P/B is ranked higher than
57% of the 935 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.44 vs. TKPYY: 2.13 )
Ranked among companies with meaningful P/B only.
TKPYY' s P/B Range Over the Past 10 Years
Min: 1.23  Med: 1.54 Max: 2.44
Current: 2.13
1.23
2.44
P/S 2.44
TKPYY's P/S is ranked higher than
54% of the 936 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.60 vs. TKPYY: 2.44 )
Ranked among companies with meaningful P/S only.
TKPYY' s P/S Range Over the Past 10 Years
Min: 1.67  Med: 2.21 Max: 12.29
Current: 2.44
1.67
12.29
PFCF 81.26
TKPYY's PFCF is ranked lower than
82% of the 468 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 30.49 vs. TKPYY: 81.26 )
Ranked among companies with meaningful PFCF only.
TKPYY' s PFCF Range Over the Past 10 Years
Min: 8.24  Med: 16.69 Max: 1688.05
Current: 81.26
8.24
1688.05
POCF 47.65
TKPYY's POCF is ranked lower than
75% of the 629 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 22.33 vs. TKPYY: 47.65 )
Ranked among companies with meaningful POCF only.
TKPYY' s POCF Range Over the Past 10 Years
Min: 7.19  Med: 15.73 Max: 772.09
Current: 47.65
7.19
772.09
EV-to-EBITDA 161.06
TKPYY's EV-to-EBITDA is ranked lower than
96% of the 839 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.61 vs. TKPYY: 161.06 )
Ranked among companies with meaningful EV-to-EBITDA only.
TKPYY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -355.6  Med: 11.45 Max: 172.9
Current: 161.06
-355.6
172.9
Current Ratio 1.50
TKPYY's Current Ratio is ranked lower than
68% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.27 vs. TKPYY: 1.50 )
Ranked among companies with meaningful Current Ratio only.
TKPYY' s Current Ratio Range Over the Past 10 Years
Min: 1.21  Med: 2.54 Max: 4
Current: 1.5
1.21
4
Quick Ratio 1.22
TKPYY's Quick Ratio is ranked lower than
63% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. TKPYY: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
TKPYY' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 2.11 Max: 3.64
Current: 1.22
1
3.64
Days Inventory 188.89
TKPYY's Days Inventory is ranked lower than
77% of the 643 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.46 vs. TKPYY: 188.89 )
Ranked among companies with meaningful Days Inventory only.
TKPYY' s Days Inventory Range Over the Past 10 Years
Min: 124.74  Med: 157.06 Max: 180.99
Current: 188.89
124.74
180.99

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.02
TKPYY's Dividend Yield is ranked higher than
81% of the 688 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. TKPYY: 3.02 )
Ranked among companies with meaningful Dividend Yield only.
TKPYY' s Dividend Yield Range Over the Past 10 Years
Min: 1.55  Med: 4.41 Max: 5.83
Current: 3.02
1.55
5.83
Dividend Payout 2.58
TKPYY's Dividend Payout is ranked lower than
98% of the 419 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.32 vs. TKPYY: 2.58 )
Ranked among companies with meaningful Dividend Payout only.
TKPYY' s Dividend Payout Range Over the Past 10 Years
Min: 0.89  Med: 1.92 Max: 7.35
Current: 2.58
0.89
7.35
Forward Dividend Yield 2.97
TKPYY's Forward Dividend Yield is ranked higher than
79% of the 610 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.60 vs. TKPYY: 2.97 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.96
TKPYY's Yield on cost (5-Year) is ranked higher than
73% of the 686 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.86 vs. TKPYY: 2.96 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TKPYY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.55  Med: 4.41 Max: 5.83
Current: 2.96
1.55
5.83
3-Year Average Share Buyback Ratio 0.10
TKPYY's 3-Year Average Share Buyback Ratio is ranked higher than
81% of the 462 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -2.90 vs. TKPYY: 0.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TKPYY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -0.1  Med: 0.10 Max: 3.2
Current: 0.1
-0.1
3.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 11.85
TKPYY's Price/Tangible Book is ranked lower than
78% of the 909 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.74 vs. TKPYY: 11.85 )
Ranked among companies with meaningful Price/Tangible Book only.
TKPYY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.85  Med: 6.50 Max: 13.07
Current: 11.85
1.85
13.07
Price/Projected FCF 1.77
TKPYY's Price/Projected FCF is ranked higher than
84% of the 549 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.22 vs. TKPYY: 1.77 )
Ranked among companies with meaningful Price/Projected FCF only.
TKPYY' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.47  Med: 0.94 Max: 1.82
Current: 1.77
0.47
1.82
Price/Median PS Value 1.16
TKPYY's Price/Median PS Value is ranked higher than
52% of the 924 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. TKPYY: 1.16 )
Ranked among companies with meaningful Price/Median PS Value only.
TKPYY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.81  Med: 0.99 Max: 5.15
Current: 1.16
0.81
5.15
Earnings Yield (Greenblatt) (%) -2.49
TKPYY's Earnings Yield (Greenblatt) (%) is ranked lower than
77% of the 723 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. TKPYY: -2.49 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TKPYY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -2.45  Med: 8.30 Max: 23.8
Current: -2.49
-2.45
23.8
Forward Rate of Return (Yacktman) (%) -21.79
TKPYY's Forward Rate of Return (Yacktman) (%) is ranked lower than
91% of the 325 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.77 vs. TKPYY: -21.79 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TKPYY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -30.8  Med: -18.50 Max: 17.2
Current: -21.79
-30.8
17.2

More Statistics

Revenue(Mil) $15152
EPS $ -0.81
Beta0.35
Short Percentage of Float0.00%
52-Week Range $21.51 - 27.52
Shares Outstanding(Mil)1572.32

Analyst Estimate

Mar16 Mar17
Revenue(Mil) 17,315 17,834
EPS($) 1.08 1.23
EPS without NRI($) 1.08 1.23

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:TKD.Germany, 4502.Japan,
Takeda Pharmaceutical Co Ltd was founded on June 12, 1781 and was incorporated on January 29, 1925. The Company is primarily engaged in the any manufacture and sale of pharmaceuticals, food supplements, and chemical products such as polyurethane. The Company also produces food, agrochemicals, and environment-related products such as pollution detectors. It is also engaged in the research, development, and promotion of its products through its related companies in the US, Europe, and Asia.
» More Articles for TKPYY

Headlines

Articles On GuruFocus.com
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 
5 Popular Asian Stocks Held By the Gurus Apr 16 2015 
Don't Quit on Teva Just Yet Feb 20 2014 
Soros´ Bet on Teva’s Transition (A Transition for Better or for Worse?) Dec 18 2013 
T. Rowe Price Japan Fund Top 5 New Buys Oct 17 2013 

More From Other Websites
Mersana plans human trials of first cancer drug by this summer Feb 08 2016
Japan Takes Aim at Ballooning Drug Prices as Costs Strain Budget Feb 07 2016
FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix®... Feb 03 2016
Takeda Pharmaceutical Co., Ltd. – Value Analysis (US OTC:TKPYY) : February 3, 2016 Feb 03 2016
Takeda Assembles Team to Evaluate Zika Vaccine Possibilities Feb 02 2016
FDA Approves Takeda's Dexilant SoluTab (dexlansoprazole) Jan 27 2016
Glaxo evaluating possibility of using vaccine technology for Zika Jan 25 2016
Asia's Biggest Drugmaker Eyes Greener Shores as Fortunes Fade at Home Jan 13 2016
Orexigen Targets Profitability by 2018, Focus on Contrave Jan 12 2016
This 230-year-old Japanese drugmaker wants to turn into 'a 33,000-person startup' Jan 12 2016
Big Brooklyn Park biotech factory sold again, this time to Takeda Jan 06 2016
Takeda Acquires U.S. Biologics Manufacturing Facility Jan 05 2016
Takeda, Teva Reveal Outlook of Japanese Business Venture Dec 28 2015
Teva Pharmaceutical: Joint Venture With Takeda Will Be 'Instantly Accretive' To 2016 EPS And Beyond Dec 28 2015
CORRECTING and REPLACING Takeda Provides Further Information about Its New Business Venture with... Dec 27 2015
INSERTING and REPLACING Takeda Provides Further Information about its New Business Venture with Teva Dec 27 2015
AstraZeneca PLC -- Moody's downgrades AstraZeneca to A3, stable outlook Dec 18 2015
AstraZeneca Invests in China, To Buy Respiratory Business Dec 17 2015
Stock Exchange: Top Asia Equities Movers Dec 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK